HS
BBOT

HighVista Strategies’s BridgeBio Oncology BBOT Stock Holding History

HighVista Strategies’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$700K Sell
78,187
-151,076
-66% -$1.62M 0.19% 135
2025
Q4 		$2.87M Buy
+229,263
New +$2.78M 0.74% 46

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighVista Strategies's BBOT Position: Q1 2026 in Review

HighVista Strategies reduced its BridgeBio Oncology (BBOT) stake by 66% in Q1 2026, selling an estimated $1.62M and leaving 78,187 shares worth $700K. The position accounts for 0.19% of the portfolio, ranked #135.

HighVista Strategies first reported a position in BBOT in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.87M in Q4 2025. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • HighVista Strategies held 78,187 shares of BridgeBio Oncology worth $700K as of Q1 2026.
  • HighVista Strategies sold 151,076 BridgeBio Oncology shares in Q1 2026, an estimated $1.62M.
  • BridgeBio Oncology made up 0.19% of HighVista Strategies's portfolio in Q1 2026, its #135 holding.
  • HighVista Strategies first reported a position in BridgeBio Oncology in Q4 2025 and has held it in 2 quarters since.
  • HighVista Strategies's BridgeBio Oncology position peaked at $2.87M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.